• Communications

• News
• Partners in Health Update
• NJ Minimum Standards and Health Care Reform
• Provider Bulletins
• Coding Guidelines & Policy Update
• Provider Publication Cumulative Index
• Love Settlement

• Policies and Guidelines

• Claims and Billing

• Interactive Tools and Resources

• Pharmacy Information

• Resources for Patient Management

• Contact Information

Annual Synagis^® (Palivizumab) Distribution Program

We are pleased to announce the Synagis^® (palivizumab) distribution program for the 2010-2011 respiratory syncytial virus (RSV) season, which is November through April in the United States. According to the Centers for Disease Control and Prevention, RSV is the most common cause of bronchiolitis and pneumonia among children younger than 1.

During the RSV season, we will approve the monthly administration of Synagis^® (palivizumab) for at-risk children younger than 2. Synagis^® is intended to decrease the morbidity and mortality associated with RSV lower respiratory tract disease in at-risk children, which includes children with one of the following conditions or risk factors:

• chronic lung disease of prematurity (CLD, formerly called bronchopulmonary dysplasia);
• history of preterm birth (< 35 weeks 0 days gestation);
• congenital heart disease;
• severe neuromuscular disease;
• congenital abnormalities of the airway.

Please refer to the article in the September edition of Partners in Health Update^SM for recommendations for premature infants as well as information about how to obtain Synagis^® (palivizumab) for use in your office.

Note: Synagis^® (palivizumab) is not effective in the treatment of RSV disease, and it is not approved for this indication.